Does Moderna Need to Start Making Money?
(NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.
However, a lot has changed in the past few years. Although Moderna's COVID-19 vaccines remain its primary revenue stream, sales are just a fraction of what they were during the pandemic. Plus, the company is losing money hand over fist, posting a $2.8 billion net loss in 2025 and expecting billions in losses in 2026 as well.
Based on this, you might think Moderna would be a terrible investment. But I'm not sure that's the case, and there are three main reasons why.
Source Fool.com
Moderna Inc. Stock
€47.52
-3.260%
With 9 Buy predictions and 8 Sell predictions the community is currently undecided on Moderna Inc..
However, we have a potential of -55.8% for Moderna Inc. as the target price of 21 € is below the current price of 47.52 €.
